Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcome measures in osteoarthritis: randomized controlled trials.

Vibeke Strand1, Ariella Kelman

  • 1Division of Immunology and Rheumatology, Stanford University, 306 Ramona Road, Portola Valley, CA 94028, USA. vstrand@aol.com

Current Rheumatology Reports
|January 10, 2004
PubMed
Summary

Understanding minimum clinically important differences (MCID) in osteoarthritis (OA) outcome measures is crucial for interpreting treatment effects. These guidelines help assess if statistically significant changes translate to meaningful improvements for patients in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interobserver variability in synovial tissue biopsy markers in Rheumatoid Arthritis: Results from OMERACT special interest group on synovial tissue biopsy.

Seminars in arthritis and rheumatism·2026
Same author

Qualitative interview study in patients with SLE to assess patient perception of fatigue and skin-related symptoms.

Lupus science & medicine·2026
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.

Annals of the rheumatic diseases·2026
Same author

Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).

Rheumatology and therapy·2026
Same author

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY study.

Modern rheumatology·2026

Area of Science:

  • Rheumatology
  • Clinical Trials Methodology
  • Health Outcomes Research

Background:

  • Osteoarthritis (OA) clinical trials commonly use patient-reported outcomes for physical function and health-related quality of life (HRQOL).
  • Interpreting the clinical significance of treatment effects requires understanding minimum clinically important differences (MCID).

Purpose of the Study:

  • To review accepted outcome measures in OA randomized controlled trials (RCTs).
  • To discuss the derivation and application of MCID values for interpreting treatment efficacy in OA.

Main Methods:

  • Review of patient-reported outcome measures used in OA RCTs.
  • Analysis of MCID definitions derived from studies involving physical therapy, NSAIDs, and COX-2 inhibitors.
  • Evaluation of the Western Ontario and McMaster Osteoarthritis Index (WOMAC) and SF-36 in OA.

Related Experiment Videos

Main Results:

  • Validated OA outcome measures include pain, disease activity, physical function, and HRQOL assessments.
  • MCID definitions provide guidelines for interpreting mean changes in treatment groups but not necessarily for individual patients.
  • The WOMAC is a valid, reliable, and sensitive measure in OA, correlating with the generic SF-36 HRQOL measure.

Conclusions:

  • Understanding MCID is essential for informed therapeutic decision-making in OA.
  • MCID values aid in comparing treatments and patient populations but require careful interpretation.
  • Methodological considerations are important when evaluating non-pharmacologic interventions and their MCID.